Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Abbott Laboratories (ABT:US) allegedly engaged in racketeering when it led an effort to market the epilepsy drug Depakote for unapproved uses, according to a federal court complaint filed in Chicago. The pharmaceutical company last year agreed to pay $1.6 billion to settle state and federal claims it promoted the drug’s use to treat bi-polar mania and to prevent migraine headaches. “Unfortunately, these sanctions were insufficient to compensate” for harm caused to injured claimants, according to today’s complaint by three health-benefit plans seeking to represent those claimants as a group.
Help employers find you! Check out all the jobs and post your resume.
Abbott Laboratories (ABT:US) allegedly engaged in racketeering when it led an effort to market the epilepsy drug Depakote for unapproved uses, according to a federal court complaint filed in Chicago. The pharmaceutical company last year agreed to pay $1.6 billion to settle state and federal claims it promoted the drug’s use to treat bi-polar mania and to prevent migraine headaches. “Unfortunately, these sanctions were insufficient to compensate” for harm caused to injured claimants, according to today’s complaint by three health-benefit plans seeking to represent those claimants as a group.
Help employers find you! Check out all the jobs and post your resume.
